ProQR Announces Important Planned Changes to Board Composition
ProQR Therapeutics will rotate co-founder Dinko Valerio and director Alison Lawton off its board at the company’s 2026 annual...
Verrica Announces Ycanth® Launch in Japan for Molluscum
Torii Pharmaceutical, a Shionogi subsidiary, has launched Ycanth in Japan for molluscum contagiosum following Japanese approval in September 2025....
Biosyent to Acquire Oral Science in a New Growth Strategy
BioSyent is acquiring Oral Science, a Canadian dental-focused distributor, for $25.5 million in cash and stock, with additional contingent...
Memo Therapeutics & CSL in IgG Technology Collaboration
Memo Therapeutics has signed a strategic collaboration and exclusive option-to-license agreement with CSL to advance recombinant polyclonal IgG products...
Inotiv Reports First Quarter 2026 Financial Results & Update
Inotiv posted first-quarter fiscal 2026 revenue of $120.9 million, up 0.8% year over year, as double‑digit growth in Discovery...
Veru to Report Q1 Fiscal 2026 Financial Results Feb 11
Veru plans to initiate a 200-patient Phase 2b study of enobosarm as an add-on to GLP-1 receptor agonists in...
Denali’s ETV Shows Progress in Lysosomal Disorder Trials
Denali Therapeutics unveiled new data across its lysosomal storage disorder portfolio and confirmed commercial readiness ahead of an April...
Ocular Therapeutix Q4 and Full Year 2025 Financial Results
Ocular Therapeutix will unveil 52-week topline data from SOL-1, its Phase 3 superiority trial of the intravitreal axitinib hydrogel...
Tiziana Publishes Clinical Results for Intranasal Foralumab
Tiziana Life Sciences’ intranasal foralumab has cleared an important credibility hurdle with the peer-reviewed publication of its open-label study...
Ascendis Pharma to Report Full Year 2025 Financial Results
Ascendis Pharma will report full-year 2025 results and host a business update on February 11, 2026, after the U.S....